223 related articles for article (PubMed ID: 38231530)
1. Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.
Abujamous L; Soltani A; Al-Thawadi H; Agouni A
Biomol Biomed; 2024 Mar; 24(2):230-237. PubMed ID: 38231530
[TBL] [Abstract][Full Text] [Related]
2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
3. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
5. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
6. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Tang H; Kulkarni S; Peters C; Eddison J; Al-Ani M; Madhusudan S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108451
[TBL] [Abstract][Full Text] [Related]
7. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
8. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract][Full Text] [Related]
9. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Dasa SSK; Diakova G; Suzuki R; Mills AM; Gutknecht MF; Klibanov AL; Slack-Davis JK; Kelly KA
Theranostics; 2018; 8(10):2782-2798. PubMed ID: 29774075
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
11. Current trends in chemotherapy for advanced ovarian cancer.
Takahashi N; Takekuma M
Jpn J Clin Oncol; 2022 Aug; 52(8):806-815. PubMed ID: 35521913
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
13. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
15. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
16. The roles and limitations of bevacizumab in the treatment of ovarian cancer.
Nakai H; Matsumura N
Int J Clin Oncol; 2022 Jul; 27(7):1120-1126. PubMed ID: 35477830
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of PARP inhibitors in ovarian cancer.
Xie H; Wang W; Xia B; Jin W; Lou G
Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
[TBL] [Abstract][Full Text] [Related]
18. Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective.
Li N; Liu Q; Tian Y; Wu L
J Gynecol Oncol; 2022 Nov; 33(6):e86. PubMed ID: 36335989
[TBL] [Abstract][Full Text] [Related]
19. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
20. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
